Trial reportEuropean heart journal2010
Dronedarone in patients with congestive heart failure: insights from ATHENA.
Trial report in European heart journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 71 citations in OpenAlex.
- Atrial Fibrillation and HFrEF: Cause, Consequence, or Both?Biomedicines · 2026Review
- Catheter Ablation as an Early Rhythm-control Strategy in Patients with Atrial Fibrillation and Heart Failure.Arrhythmia & electrophysiology review · 2026Review
- Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document.European journal of heart failure · 2025Review
- Atrial Fibrillation (AF) and Heart Failure With Preserved Ejection Fraction (HFpEF): Advances and Challenges.Journal of cardiovascular electrophysiology · 2025Review
- Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.European journal of heart failure · 2022Article
- Atrial fibrillation and its pernicious role in heart failure with preserved ejection fraction: a new frontier in interventional electrophysiology.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2018Article
- Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation.Experimental animals · 2017Article
- Atrial fibrillation in heart failure: The sword of Damocles revisited.World journal of cardiology · 2013Article
- Atrial fibrillation in heart failure: an innocent bystander?Current cardiology reviews · 2012Review
- Post-ATHENA and beyond.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2011Article
- Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Materia socio-medica · 2011Article
- Management of atrial fibrillation: focus on the role of dronedarone.Open access emergency medicine : OAEM · 2011Review
- Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter.Clinical Medicine Insights. Cardiology · 2011Article
- [Dronedarone].Herzschrittmachertherapie & Elektrophysiologie · 2010Review
- Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.Journal of atrial fibrillationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDronedarone is a new multichannel blocking antiarrhythmic drug for treatment of atrial fibrillation (AF). In patients with recently decompensated congestive heart failure (CHF) and depressed LV function, the drug was associated with excess mortality compared with a placebo group. The present study aimed to analyse in detail the effects of dronedarone on mortality and morbidity in AF patients CHF. METHODS AND
resultsWe performed a post hoc analysis of ATHENA, a large placebo-controlled outcome trial in 4628 patients with paroxysmal or persistent AF, to evaluate the relationship between clinical outcomes and dronedarone therapy in patients with stable CHF. The primary outcome was time to first cardiovascular (CV) hospitalization or death. There were 209 patients with NYHA class II/III CHF and a left ventricular ejection fraction < or =0.40 at baseline (114 placebo, 95 dronedarone patients). A primary outcome event occurred in 59/114 placebo patients compared with 42/95 dronedarone patients [hazard ratio (HR) 0.78, 95% CI = 0.52-1.16]. Twenty of 114 placebo patients and 12/95 dronedarone patients died during the study (HR 0.71, 95% CI = 0.34-1.44). Fifty-four placebo and 42 dronedarone patients were hospitalized for an intermittent episode of NYHA class IV CHF (HR = 0.78, 95% CI = 0.52-1.17).
conclusionIn this post-hoc analysis of ATHENA patients with AF and stable CHF, dronedarone did not increase mortality and showed a reduction of CV hospitalization or death similar to the overall population. However, in the light of the ANtiarrhythmic trial with DROnedarone in Moderate to severe CHF Evaluating morbidity DecreAse study, dronedarone should be contraindicated in patients with NYHA class IV or unstable NYHA classes II and III CHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.